MedTrace Logo

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-12-11

No results posted yet for this study

Summary

Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.

Conditions

Interventions

DRUG

Alprazolam

1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)

OTHER

control group

control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Stephen N Davis, MD · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592332 on ClinicalTrials.gov